Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Immunotherapy
30 Articles Available
1
2
Can't find what you're looking for? Try our
advanced search
.
Immunotherapy
Researchers Report SX-682 Could Enhance Multiple Forms of T Cell-Based Immunotherapies in Solid Tumors
PR-M04-19-NI-040
Investment
Portage Makes Additional Investment in Stimunity S.A, a Paris-based Cancer Immunotherapy Company
PR-M03-19-NI-081
Immunotherapy
Collaborating for Immunotherapy Development
PAP-Q1-2019-NI-007
Immunotherapy
AIVITA Identifies Mechanism to Enhance Patient Response Rate to Next Generation Cancer Stem Cell Immunotherapy
PR-M02-19-NI-031
Immunotherapy
Global Cancer Immunotherapy Market: Focus on Pharmaceutical Products, Therapeutic Indication, Competitive Landscape and Region - Analysis and Forecast, 2018-202
PR-M02-19-NI-024
Immuno-oncology
GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment
PR-M01-19-NI-023
Immunotherapy
Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche
PR-M12-18-NI-012
Cell Therapy
Immunotherapy Pioneers a Unveil Updated Efficacy Data of Tisagenlecleucel, plus Checkpoint Inhibitor Research to Boost Response of CAR T-cell Gene Immunotherapy
PR-M12-18-NI-011
Immunotherapy
Patient Weight Can Impact the Effectiveness of Cancer Immunotherapies
PAO-M11-18-NI-022
Immunotherapy
I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy
PR-M11-18-NI-014
Immunotherapy
Guardant Health Presents Data on Immunotherapy-related Biomarkers MSI and TMB in blood of advanced cancer patients
PR-M10-18-NI-075
Immunotherapy
eTheRNA Opens State-of-the-art Manufacturing Facility in Belgium to Support the Development of its TriMix-based mRNA Cancer Immunotherapies
PR-M10-18-NI-042
Immunotherapy
Increasing Number of Cancer Cases to Fuel the Global Cancer Immunotherapy Market Growth
PR-M10-18-NI-025
Immunotherapy
Nobel Prize in Medicine Goes to Immunotherapy Developers
PAO-M10-18-NI-003
Immunotherapy
Cancer Immunotherapy Treatment Market on the Rise as R&D Increases
PR-M09-18-NI-086
Immunotherapy
New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients
PR-M07-18-NI-070
Immunotherapy
India Gets First Immunotherapy for Lung Cancer
PAO-M06-18-NI-022
Clinical Trials
Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients
PR-M06-18-NI-072
Immunotherapy
Cancer Immunotherapies Reach Patients More Quickly Than Other Drugs
PAO-M05-18-NI-013
Immunotherapy
Medigene, Bluebird Bio Collaboration on TCR Immunotherapy Extended
PAO-M05-18-NI-010
Immunotherapy
Immunotherapy Prior to Surgery Shows Promise in Fight Against Lung Cancer
PAO-M04-18-NI-016
Immuno-oncology
Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
PR-M04-18-NI-40
CAR T
Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
PR-M04-18-NI-022
Immunotherapy
Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis
PR-M03-18-NI-082
1
2
»
